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| INTRODUC TI ON
Hepatocellular carcinoma is the sixth most common cancer and the third leading cause of cancer-related mortality worldwide. 1 Although some progress has been made in basic and clinical research on HCC, including identification of several diagnostic markers and detection of some genes related to the invasion and metastasis of HCC, 2 the underlying mechanism of HCC remains to be determined. 3, 4 Lymphoid-specific helicase belongs to the SNF2 family of chromatin-remodeling ATPases and plays a critical role in maintaining DNA methylation in development in plants and mammals. [5] [6] [7] [8] Recently, LSH has been identified as one of 5-hydroxymethylcytosine (5-hmC) readers in mouse embryonic stem cells, neuronal progenitor cells, and adult mouse brain. 9 Interestingly, LSH maintained genome stability in mammalian somatic cells and also served as a driver in several cancers. [10] [11] [12] [13] [14] [15] However, its role in the progression of HCC remains to be determined.
In the present study, we examined the role of LSH in the growth, invasion and metastasis of HCC cells. We also explored the mechanisms of transcription regulation of LSH. We finally established the relationship between LSH expression and HCC prognosis.
| MATERIAL S AND ME THODS

| Cell lines and cell culture
Human HCC cell lines HCCLM3 (established by the Liver Cancer
Institute, Zhongshan Hospital, Fudan University), Huh7, PLC/PRF/5, and Hep3B (purchased from ATCC and raised in Liver Cancer Institute, Zhongshan Hospital, Fudan University) were used in this study. Hep3B cells were cultured in DMEM (HyClone, Logan, UT, USA). HCCLM3, Huh-7, and PLC/PRF/5 cell lines were cultured in DMEM containing 10% FBS (YEASEN, Shanghai, China) supplemented with 100 IU/mL penicillin and 100 μg/mL streptomycin. All cell lines were incubated at 37°C in a humidified atmosphere with 5% CO 2 . All cell culture media and FBS were obtained from Gibco (Invitrogen, Carlsbad, CA, USA).
Other supplies were obtained from Corning (Corning, NY, USA). This study was approved by the Ethics Committee at Zhongshan Hospital of Fudan University. Full informed consent was obtained from all patients.
| Quantitative real-time polymerase chain reaction and western blot
Quantitative real-time polymerase chain reaction and WB were carried out as previously described. 16 Primary antibodies against CENPF (20982-1-AP) and LSH (11955-1-AP) were purchased from Proteintech (Chicago, IL, USA). Sequences (5′-3′) of primers used for qPCR are listed below.
Lymphoid-specific helicase, forward primer GAGGCTCC AGCAATGGTTGAA, reverse primer CGCTCTCTCTCTAGTCCAGCA.
CENPF, forward primer CTCTCCCGTCAACAGCGTTC, reverse primer GTTGTGCATATTCTTGGCTTGC.
Sequences (5′-3′) of primers used for ChIP-qPCR are listed below.
CENPF, forward primer TCTGCTCGGGTTCAAACTGG, reverse primer TGTGAGTCCGTGACCGAGTA.
| Transfection and clone selection
Lymphoid-specific helicase, LSH-shRNA, and CENPF-shRNA expression lentiviral vectors were purchased from Shanghai GeneChem
Co. (Shanghai, China), and the lentiviral vector was transfected using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Transfected HCC cells were selected using puromycin for 7 days prior to assay. 
| Patients and follow up
| Immunohistochemistry and tissue microarrays
Immunohistochemistry was carried out as described elsewhere. 16 Tissue microarrays (TMA) were constructed as previously described. 17 Primary antibodies against CENPF (20982-1-AP) and LSH (11955-1-AP) were obtained from Proteintech.
| Cell migration, Matrigel invasion assay, cell viability, and colony formation assay
Cell migration was tested by wound-healing experiment. Matrigel invasion assay was obtained from BD Biosciences (Franklin Lakes, NJ, USA).
Cell viability was measured by CCK-8 assay (YEASEN, Shanghai, China).
Matrigel invasion assay and CCK-8 assay were carried out according to the manufacturers' protocols. Colony formation assay and woundhealing experiment were done as previously described. 16 
| Flow cytometry assay
Cell cycle and apoptosis were detected by flow cytometry (FCM;
Becton Dickinson, Franklin Lakes, NJ, USA).
| Tumor xenograft assay
Hepatocellular carcinoma cells were used to establish s.c. xenograft tumor models. Tumor growth was monitored twice weekly, and mice were killed after 4 weeks. Tumors were measured in two dimensions.
| Chromatin immunoprecipitation
Chromatin immunoprecipitation was carried out as follows. Briefly, DNA was cross-linked using 1% formalin, the cells were lysed in SDS buffer, and DNA was fragmented by sonication. ChIP for LSH was done using an anti-Flag antibody (SAB4301135; Sigma Chemical Co., St Louis, MO, USA).
| High-throughput sequencing
The resulting DNA library was sequenced on Illumina Hiseq2500 (San Diego, CA, USA). The results obtained were analyzed using Hisat2, StringTie and Ballgown tools to obtain deferentially expressed genes. The UCSC Genome Browser (University of California, Santa
Cruz) was used for data visualization. 
| Statistical analysis
| RE SULTS
| Lymphoid-specific helicase is overexpressed in tumor tissues and its expression correlates with overall survival of HCC patients
To explore the expression and potential role of LSH in HCC, we first used the publicly available HCC database (GEPIA, http://gepia.
cancer-pku.cn) to analyze LSH mRNA expression between tumor specimens and normal tissues. 18 As shown in Figure 1A , LSH mRNA expression was significantly elevated in HCC tissues compared to para-tumor liver tissues. Importantly, LSH mRNA expression was negatively associated with overall survival (P = 0.018, Figure 1B) and relapse-free survival (P < 0.001, Figure 1B ), suggesting that LSH expression may be an indicator of the prognosis of HCC patients.
Lymphoid-specific helicase expression was significantly higher in tumor tissues than in para-tumor tissues ( Figure 1C ,D). To validate the relationship between LSH expression and the prognosis of HCC patients, 208 HCC tissues and corresponding para-tumor liver tissues were subjected to IHC staining for LSH. Positive staining was located in the nucleus of tumor cells ( Figure 1E ). We further analyzed the correlation between LSH expression and clinical features, as shown in Table 1 . Furthermore, Kaplan-Meier analysis showed that higher level of LSH expression was associated with shorter overall survival (OS) (P < 0.001; Figure 1F ) and disease-free survival (DFS) (P < 0.001; Figure 1F ). Moreover, univariate and multivariate analyses showed that LSH expression was an independent prognostic factor of OS for patients with HCC (P = 0.001; Table 2 ). Taken together, these data indicate that upregulation of LSH contributes to recurrence and is associated with a poorer prognosis in HCC.
| Knockdown of LSH expression inhibits cell growth and invasion of HCC cells in vitro and in vivo
To further explore the function of LSH in HCC, we analyzed its ex- CCK-8 assay showed that cell proliferation was significantly decreased in LSH knockdown cells ( Figure 2C ). The capacity for colony formation of HCC cells was clearly reduced after LSH was knocked down, whereas the capacity for colony formation was enhanced when LSH was overexpressed ( Figure 2D ). Flow cytometry analyses showed that the proportion of cells in G0/G1 in HCCLM3 cells was higher than that of HCCLM3-shLSH and vice versa ( Figure 2E ). Similarly, downregulated expression of LSH reduced the increased rate of apoptosis ( Figure 2F ). Invasion capacity was also inhibited in LSH knockdown Bold values are statistically significant (P < 0.05). AFP, alpha fetoprotein; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LSH, lymphoid-specific helicase.
cells and enhanced in cells overexpressing LSH ( Figure 2G ). Wound healing assay showed that the migratory ability of HCC cells was significantly inhibited after LSH expression was decreased ( Figure 2H,I ).
In were analyzed by mRNA-seq, and the differentially expressed genes (>2-fold) were identified (shown in heat map, Figure 3A) . We found that 4342 differentially expressed genes overlapped in these two cells.
Then, we used to ChIP for LSH and sequence to identify the target genes of LSH in the above HCCLM3 cells transfected with two different shRNA sequences. We identified 1238 differentially expressed genes (>2-fold) and they intersected with the above 4342 overlapped differential genes. Results showed 146 overlapping genes ( Figure 3B ).
KEGG and gene ontology (GO) analyses for these 146 genes were carried out. The results showed that cell biological pathways, such as cell cycle, division, and response to drugs and hormones were increased ( Figure 3B ). Gene set enrichment analysis (GSEA) was carried out and significant pathways were identified for both up-and downregulated gene sets. As LSH is located mainly in the nucleus ( Figure 1E ), pathways related to chromosome, nuclear division and cell cycle were analyzed. Results showed knockdown of LSH obviously disrupted these pathways ( Figure 3C ). Of note, one of the genes most frequently included in these gene sets was CENPF ( Figure 3D ).
| Centromere protein F is overexpressed in HCC tissues and is positively correlated with LSH protein overexpression
Given the important role of CENPF in the cell cycle, mitosis and regulation of PLK1 activity at G2/M transition, we further explored the interaction of LSH with CENPF. We first analyzed the relationship between LSH and CENPF expression in The Cancer Genome Atlas (TCGA) database. We observed that LSH and Cenpf mRNA were consistently upregulated in HCC tissues, compared to para-tumor liver tissues ( Figure 4A ,B,
Pearson 0.69, Spearman 0.8 by cBioPortal). Moreover, survival analysis
showed that higher Cenpf expression in tumor tissues was associated with poorer prognosis in HCC patients ( Figure 4C ,D, by GEPIA).
We also investigated the expression of CENPF in 208 HCC samples and analyzed the correlation between CENPF and LSH. Results showed that CENPF expression in tumor tissues was significantly higher than that in para-tumor tissues at the level of mRNA and protein ( Figure 4E ).
Importantly, we found that increased LSH protein level is associated with increased CENPF protein level ( Figure 4F) . Furthermore, survival analysis also showed that high CENPF expression in tumor tissues was associated with short overall survival (OS) (P < 0.001) and DFS (P < 0.001; Figure 4G ). Similarly, univariate and multivariate analyses were carried out and showed that CENPF expression was an independent prognostic factor of OS for patients with HCC (P = 0.001; Table 3 ). 
F I G U R E 2 Knockdown of lymphoid-specific helicase (LSH) expression inhibits cell growth and invasion of hepatocellular carcinoma (HCC) cells in vitro and in vivo. A, Western blot (WB) and qPCR experiments for testing LSH in
F I G U R E 4
Centromere protein F (CENPF) is overexpressed in hepatocellular carcinoma (HCC) tissues and is positively correlated with lymphoid-specific helicase (LSH) protein overexpression. A, CENPF and LSH mRNA expression. B, Correlation of mRNA level between CENPF and LSH. C and D, Online analysis for overall survival (OS) and disease-free survival (DFS) shows that higher CENPF expression indicates a poorer prognosis. E, mRNA and protein levels tested by qPCR and western blot (WB Bold values are statistically significant (P < 0.05). AFP, alpha fetoprotein; CENPF, centromere protein F; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.
TA B L E 3
Correlation between CENPF and clinicopathological characteristics in 208 HCC patients Considering the positive relationship between LSH and CENPF expression, we divided the cohorts into three subgroups based on the expression of LSH and CENPF (both high, both low, single high). We then carried out Kaplan-Meier analysis and log-rank test and found that HCC patients with high expression of both CENPF and LSH ("both high") showed the worst OS (P < 0.001) and DFS (P < 0.001), whereas the subgroup with low expression of both CENPF and LSH ("both low") had the best prognosis ( Figure 4H ). These clinical data indicate that LSH probably plays a substantial role in HCC in a CENPF-dependent manner.
| Lymphoid-specific helicase binds to the transcription start site of Cenpf and promotes growth of HCC in a CENPF-dependent way
To further address the interaction of LSH with CENPF, we thoroughly analyzed the above ChIP-seq data. We observed that a specific peak of LSH overlapped at the transcription start site (TSS) of the cenpf gene ( Figure 5A ), which is located at chr1:
214 776 582-214 776 968, and verified these results by qPCR using These results showed that CENPF was one of the downstream targets of LSH. Functional analysis also showed that cell proliferation and migration influenced by LSH overexpression could be partially inhibited by CENPF knockdown ( Figure 5F ).
| D ISCUSS I ON
Lymphoid-specific helicase plays a critical role in the development of mammals through maintaining DNA methylation and remodeling chromatin. 6, 7 Recent studies also showed upregulated expression of LSH in several malignant tumors, such as prostate cancer, melanoma, head and neck cancer; and LSH is probably involved in the tumor progression. 12 Moreover, LSH has been reported to be linked to glioma biology as a downstream target of LRP6-GSK3β-E2F1 signaling; 19 however, the detailed mechanism of LSH and its downstream targets in cancers still need to be thoroughly addressed. A recent study has reported that by altering nucleosome occupancy at the nucleosome-free region (NFR) and enhancer, LSH epigenetically suppresses multiple tumor suppressor genes including E-cadherin, FBP1, IGFBP3, XAF1 and CREB3L3 to promote HCC progression. 20 In the present study, we first showed upregulated expression of LSH in HCC samples Although both we and a previous report found that LSH promotes HCC progression, we have formulated a new explanation for the mechanism. 20 In addition to its role in DNA methylation, LSH is also considered a nucleoprotein. Our important finding from the present study is that LSH plays a key role in tumor growth through regulation of downstream target CENPF. In the present study, we used a combination of mRNA-seq with ChIP-seq and confirmed the interaction of LSH and CENPF. qPCR analysis then showed that LSH combined with the cenpf TSS area. Importantly, modification of LSH expression in HCC cells could correspondingly alter the expression of CENPF. In turn, alteration of CENPF expression did not influence LSH expression, indicating that CENPF is a downstream target of LSH (summarized in Figure 6 ). CENPF protein is a component of the nuclear matrix during the G2 phase of interphase and is required for kinetochore function and chromosome segregation in mitosis. Previous studies have shown that CENPF is upregulated in breast cancer, 21 nasopharyngeal cancer, 22 hepatocellular carcinoma, 23 esophageal squamous cell carcinoma, 24 gastrointestinal stromal tumors 25 and, in some cases it is associated with aggressive tumor phenotype and poor survival. 21, 22, 24 However, the mechanism of CENPF expression control remains unclear. In the present study, inhibition of LSH in HCC cells significantly decreased the proportion of cells in G0/G1. More importantly, increased expression of CENPF could rescue the growth, migration and invasion of HCC cells. Clinically, HCC patients expressing high CENPF and LSH showed the poorest prognosis. These data not only broaden our understanding of the mechanism of the role of LSH in tumor progression, but also provide convincing evidence to support the notion that LSH may be a novel therapeutic target for HCC patients.
F I G U R E 6 Schema of lymphoidspecific helicase (LSH) regulation of centromere protein F (CENPF) by a protein-DNA interaction. HCC, hepatocellular carcinoma
In conclusion, LSH promotes tumor progression through transcription regulation of cenpf, and may be an effective therapeutic target for a subgroup of HCC patients with high expression of LSH.
The datasets supporting the conclusions of this article are included within the article and its supplementary material. The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.
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